Article Text

other Versions

Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: A 3-month, double-blind, randomized, placebo-controlled, parallel-group, proof-of-concept study
  1. George AW Bruyn (gawbruyn{at}
  1. Medisch Centrum Leeuwarden, Netherlands
    1. Guillermo Tate
    1. OMI Organizacion Medica de Investigacion, Buenos Aires, Argentina
      1. Francisco Caeiro
      1. Hospital Privado de Cordoba, Cordoba, Argentina
        1. Jose Maldonado-Cocco
        1. Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina
          1. Rene Westhovens
          1. U.Z, Gasthuisberg, Leuven, Belgium
            1. Hyman Tannenbaum
            1. Rheumatic Disease Centre of Montreal, Montreal, Canada
              1. Mary Bell
              1. Sunnybrook Health Science Centre, Toronto, Canada
                1. Oystein Forre
                1. Rikshospitalet, Oslo, Norway
                  1. Olav Bjorneboe
                  1. Martina Hansens Hospital, Gjettum, Norway
                    1. Paul Peter Tak
                    1. Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
                      1. Kamal H Abeywickrama
                      1. Novartis Pharma AG, Basel, Switzerland
                        1. Peter Bernhardt
                        1. Novartis Pharma AG, Basel, Switzerland
                          1. Piet LC van Riel
                          1. Universitair Medisch Centrum St Radboud, Nijmegen, Netherlands


                            Objectives: Everolimus, a proliferation signal inhibitor with disease-modifying properties, may be useful in treating rheumatoid arthritis (RA). This proof-of-concept study assessed efficacy and safety of everolimus in combination with methotrexate (MTX) in patients with refractory RA.

                            Methods: A multicenter, randomized, double-blind, placebo-controlled trial was performed in 121 patients with active RA receiving MTX. Patients were randomized to receive everolimus (6 mg/day) or placebo. The primary endpoint was the American College of Rheumatology criteria for a 20% improvement in measures of disease activity (ACR20) at 12 weeks.

                            Results: There was a rapid onsetof action and at 12 weeks the ACR20 response rate was significantly higher in the everolimus group (36.1%) than in the placebo group (16.7%) (P = 0.022). Improvements from baseline in tender and swollen joint counts, patient’s assessment of pain, and patient’s and physician’s global assessment of disease activity were significantly greater after treatment with everolimus. The most common adverse events (AEs) in the everolimus group were gastrointestinal (52.5% vs. 31.7% in the placebo group), skin (29.5% vs. 8.3%), and nervous system disorders (21.3% vs. 10.0%); AEs leading to treatment discontinuation were reported for 16.4% and 10.0% of patients, respectively. Changes in hematologic parameters, liver function tests, and lipid levels occurred more frequently with everolimus compared to placebo, but were mild and reversible.

                            Conclusions: The study indicates that everolimus plus MTX provides clinical benefit with an acceptable safety and tolerability profile. It may offer a new treatment option in RA patients with inadequate response to MTX.

                            • clinical trial
                            • combination therapy
                            • everolimus
                            • immunosuppressant
                            • rheumatoid arthritis

                            Statistics from

                            Request permissions

                            If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.